Australian Plant Proteins (APP), a company that navigated insolvency just over a year ago, has unveiled its direct-to-consumer (D2C) brand, "Nothing Else." This strategic move marks a significant foray into the retail market, driven by a burgeoning consumer appetite for protein, notably amplified by the widespread adoption of GLP-1 medications and a broader wellness consciousness. The brand’s core offering is a line of clean-label, plant-based protein isolate powders, emphasizing purity, transparency, and Australian sourcing.
The launch of Nothing Else represents a bold resurgence for APP, which was acquired by investment firm My Co, part of the Paule Family Office, in March 2025 following a period of voluntary administration in July 2024. This acquisition breathed new life into the company, allowing it to resume operations two months later and embark on a new chapter focused on consumer engagement.
A Commitment to Purity: The "Nothing Else" Philosophy
The brand’s name, "Nothing Else," is a direct reflection of its minimalist ingredient philosophy. The protein isolate powders are positioned as single-ingredient products, meaning protein isolate derived from fava beans and yellow peas is the sole component. This approach deliberately eschews the chemical extraction methods often employed in the industry, promising consumers a product free from additives, artificial flavors, and unnecessary fillers. Each 30-gram scoop delivers a substantial 25-26 grams of complete plant protein, a testament to the concentrated nature of the isolate.
Vicky Pappas, CEO of My Co, articulated the rationale behind this direct-to-consumer initiative. "Australian Plant Proteins has been manufacturing high-quality protein isolates for B2B customers for years," Pappas stated. "However, there was a clear gap for consumers who wanted direct access to a clean-label, locally grown product at an accessible price point. We saw an opportunity to deliver Australia’s first genuinely farm-to-you plant protein isolate range directly to consumers."
Pappas further emphasized the brand’s commitment to transparency and control. "By launching Nothing Else, we can offer complete transparency and control – from Wimmera-grown pulses to finished product – without the additives, flavours, or fillers common in the market," she explained. This "paddock to pouch" narrative underscores the brand’s dedication to a fully integrated and traceable supply chain.
Leveraging Vertical Integration and a Chemical-Free Process
The production of Nothing Else protein isolates is rooted in APP’s state-of-the-art facility in Horsham, Victoria. This vertical integration is a cornerstone of the brand’s value proposition, granting the company complete oversight from pulse cultivation through to the final packaging. This model not only ensures consistent quality but also cultivates a resilient supply chain, mitigating reliance on imports, third-party processors, and the complexities of international shipping.
A key differentiator for Nothing Else is its proprietary ApPro processing method. Unlike conventional plant protein isolates, which often rely on chemical solvents like hexane for extraction, APP’s ApPro process is described as a gentle, solvent-free technique. This chemical-free approach is crucial for maintaining the integrity and nutritional profile of the protein.
Phil McFarlane, co-founder and CEO of Australian Plant Proteins, elaborated on the advantages of their method. "Traditional methods leave chemical residues and can compromise protein quality, while our approach preserves the natural integrity of the plant," McFarlane explained. "The result is protein that’s highly digestible, gentle on the stomach, neutral in flavour, and smooth in texture, while delivering a premium nutritional profile with all nine essential amino acids and over 85% protein content per serve."
The resulting powders are characterized by a neutral flavor, an off-white hue, and a smooth texture. Their enhanced solubility means they can be seamlessly incorporated into a variety of culinary applications, including smoothies, oatmeal, baked goods, and savory dishes, without introducing unwanted grittiness or clumping.
McFarlane highlighted the nutritional parity with whey protein, while underscoring the plant-based advantages. "Our protein isolates are nutritionally comparable to whey… but they’re plant-based, highly digestible, neutral in flavour, and suitable for a broader range of dietary requirements, including lactose intolerance and vegan lifestyles," he stated. Furthermore, the sustainability aspect is significant: "Our solvent-free extraction process delivers a product that’s gentle on the stomach, while our pulses are grown as nitrogen-fixing rotational crops, making them inherently more sustainable than dairy production." While not directly targeting whey shortages, McFarlane positioned Nothing Else as a high-performing, locally sourced, and accessible alternative.
Capitalizing on the GLP-1 Surge and Growing Health Consciousness
The launch of Nothing Else arrives at a pivotal moment in the Australian health and wellness landscape, mirroring trends observed globally. The company is strategically tapping into the amplified demand for protein, particularly as the use of GLP-1 medications for weight management gains traction.
"We’re seeing increased demand driven by growing recognition of protein’s role in satiety, metabolic health, healthy ageing, and weight management, particularly as GLP-1 medications emphasize the importance of maintaining protein intake," McFarlane observed.
Current statistics paint a compelling picture: approximately half a million Australians are reportedly using weight-loss drugs. While the majority of the population meets their daily protein requirements, individuals on GLP-1 therapies are at a heightened risk of falling short. Research suggests that less than 10% of this demographic adequately meet their protein goals. Compounding this challenge, GLP-1 users can experience a significant decrease in muscle mass – ranging from 25% to 40% over an 8-16 month period – a rate substantially higher than that associated with non-medicated weight-loss approaches or age-related muscle loss. This presents a critical nutritional challenge that protein supplementation can help address.
Beyond the GLP-1 trend, McFarlane noted a broader shift in consumer behavior. "Consumers are also becoming more sophisticated about ingredient quality and sourcing, while the flexitarian movement has created massive demand for high-quality plant proteins that don’t compromise on performance," he said. This growing demand for plant-based options, coupled with an increasing awareness of digestive sensitivities to traditional protein sources like whey, positions Nothing Else favorably in the market. "Additionally, many consumers experience digestive discomfort with whey and are actively seeking clean alternatives that deliver the same macros without stomach issues," he added.
The Nothing Else protein isolates are available for purchase on the brand’s website at A$29.99 (approximately $21.35 USD) for a 300-gram pouch. This accessible price point aims to democratize access to high-quality, clean-label protein.
A Resilient Past, A Promising Future
The emergence of Nothing Else is a testament to Australian Plant Proteins’ resilience and strategic adaptation. The company’s journey through voluntary administration in July 2024 was a challenging period, with some industry observers attributing the difficulties to a perceived lack of government support rather than inherent company flaws. Pappas, however, attributed the situation to "a variety of contributing factors exacerbated by tough economic conditions."
The subsequent acquisition by My Co in March 2025 marked a pivotal turning point. This investment provided the necessary capital and strategic direction to stabilize and reposition the company. The transition saw the exit of APP co-founder Brendan McKeegan, while Pappas assumed a key leadership role.
"The integration has been positive and ramp-up has been strong," Pappas reported. "Continuity in operations and personnel has been critical – we’ve maintained and built upon our team and continued to support local employment in the Horsham region." This emphasis on continuity and local employment highlights a commitment to community and operational stability.
A significant development since recommencing operations is the attainment of certification for the Chinese market. This expansion into a major international market signifies growing confidence in APP’s product quality and manufacturing standards. "Since recommencement, we’ve also gained certification for China, expanding our market access while maintaining the exact same process and quality standards our customers have always relied on," Pappas stated.
Looking ahead, Pappas confirmed that APP is not currently seeking additional capital. The company’s immediate focus is on executing its established strategy. "We’re focused on executing our current strategy – growing our B2B partnerships and establishing Nothing Else as Australia’s leading clean-label, direct-to-consumer plant protein isolate brand," she concluded. This dual approach of nurturing existing B2B relationships while aggressively pursuing the D2C market underscores a comprehensive growth plan aimed at solidifying APP’s position in the evolving nutrition industry. The brand’s commitment to sustainable sourcing, chemical-free processing, and transparent labeling positions it to capture a significant share of the growing market for health-conscious and environmentally aware consumers.